Det ublindede studiet viste ingen forskel i den samlede overlevelsesrate hos patienter, der blev behandlet med rekombineret humant erytropoietin og kontrolgruppen.
In the open-label study there was no difference in overall survival between patients treated with recombinant human erythropoietin and controls.